Evidence map›Paper›PMID 39969178›Full record

ArticleMicrobiology spectrum2025

Systemic inflammation is associated with worse outcomes from SARS-CoV-2 infection but not neutralizing antibody.

Christopher W Farnsworth, Brittany Roemmich, John Prostko, Gerard Davis, Gillian Murtagh, Laurel Jackson, Christopher Jacobson, Nicolette Jeanblanc, Timothy Griffiths, Edwin Frias and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbiology spectrum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Christopher W FarnsworthDepartment of Pathology and Immunology, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA.ORCID 0000-0001-7169-3850
Brittany RoemmichDepartment of Pathology and Immunology, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA.
John ProstkoAbbott Diagnostics, Abbott Park, Illinois, USA.
Gerard DavisAbbott Diagnostics, Abbott Park, Illinois, USA.
Gillian MurtaghAbbott Diagnostics, Abbott Park, Illinois, USA.
Laurel JacksonAbbott Diagnostics, Abbott Park, Illinois, USA.
Christopher JacobsonAbbott Diagnostics, Abbott Park, Illinois, USA.
Nicolette JeanblancAbbott Diagnostics, Abbott Park, Illinois, USA.
Timothy GriffithsAbbott Diagnostics, Abbott Park, Illinois, USA.
Edwin FriasAbbott Diagnostics, Abbott Park, Illinois, USA.
David J DaghfalAbbott Diagnostics, Abbott Park, Illinois, USA.

Funding

Abbott | Abbott Diagnostics (DIAGNOSTICS AT ABBOTT)
6 · The paper itself

Abstract

Systemic inflammation is associated with COVID-19 mortality rates, but the impact of inflammation on neutralizing antibodies to severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) and on outcomes is poorly understood. This study aimed to determine the association between neutralizing antibody responses, inflammation, and clinical outcomes in hospitalized patients with COVID-19. Two hundred and eight patients presenting to the ED with symptomatic SARS-CoV-2 were included. Neutralization was assessed using the architect angiotensin-converting enzyme-2 (ACE2) binding inhibition assay, and inflammation was assessed using C reactive protein (CRP) and interleukin 6 (IL-6). Medical records were examined for 30-day mortality and 10-day intubation. Correlation between biomarkers was assessed and Kaplan-Meier curves and Cox proportional hazards models were constructed for outcomes. Thirty-seven (18%) patients died and 59 (28%) required intubation. There was a correlation between IL-6 and CRP (

Indexed as

Antibodies, NeutralizingAntibodies, ViralCOVID-19InflammationSARS-CoV-2AdultAgedAged, 80 and overAngiotensin-Converting Enzyme 2BiomarkersC-Reactive ProteinFemaleHumansInterleukin-6MaleMiddle AgedACE2 protein, humanAngiotensin-Converting Enzyme 2Antibodies, NeutralizingAntibodies, ViralBiomarkersC-Reactive ProteinIL6 protein, humanInterleukin-6adaptive immunityinflammationneutralizing antibodiesSARS-CoV-2

Identifiers

PMID39969178
PMCPMC11960045

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.